Status Epilepticus
Recent clinical, regulatory, research and industry developments relating to this disease.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2027.
Clinical MilestonesViewHide
- 2026-05-14Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)Results expected Q2 2029
- 2026-05-04Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)Results expected Q4 2027
- 2026-07-30Efficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status EpilepticusPrimary completion
- 2026-06-30Efficacy of Combined Ketamine and Levetiracetam as a Second-line Anti-seizure Medication for Generalized Convulsive Status Epilepticus in ChildrenPrimary completion
- 2026-05-20PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac ArrestPrimary completion
- 2026-07-30ClinicalEfficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status EpilepticusPrimary completion
- 2026-06-30ClinicalEfficacy of Combined Ketamine and Levetiracetam as a Second-line Anti-seizure Medication for Generalized Convulsive Status Epilepticus in ChildrenPrimary completion
- 2026-05-20ClinicalPeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac ArrestPrimary completion
- 2026-05-14ClinicalKetamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)Results expected Q2 2029
- 2026-05-04ClinicalFast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)Results expected Q4 2027
- 2025-10-14ClinicalA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status EpilepticusResults posted
- 2025-10-10ClinicalEfficacy and Safety of Perampanel in the Treatment of Refractory Status EpilepticusTerminated
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Status Epilepticus4
- Organophosphate Poisoning2
- Brain Injuries1
- Epilepsy1
- Exosomes1
- HMGB1 Protein1
- Implantable Neurostimulators1
- MicroRNAs1
Leading journals4
- The Journal of pharmacology and experimental therapeutics3
- Molecular biology reports1
- Neurology1
- The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers8
- Ramakrishnan S3
- Reddy DS3
- Singh T3
- Wu X3
- Agostini MA1
- Alexopoulos AV1
- Anderson WS1
- Barkley GL1
Affiliations (unnormalised)6
- Texas A&M University School of Medicine2
- Department of Neuroscience and Experimental Therapeutics and Institute of Pharmacology and Neurotherapeutics1
- From the Cleveland Clinic Foundation (D.R.N.1
- School of Medical Imaging1
- The Second Affiliated Hospital of Xuzhou Medical University1
- University of California1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Status epilepticus is a prolonged seizure state, or repeated seizures close enough together that recovery does not occur between episodes, typically over 20 to 30 minutes. It includes generalized tonic-clonic, nonconvulsive, simple partial, and subclinical forms. The generalized tonic-clonic subtype is described as potentially fatal and associated with neuronal injury plus respiratory and metabolic dysfunction.
The supplied grounding does not identify a specific underlying cause or aetiology for status epilepticus. It does indicate a chemically induced aspect in the literature, but no particular causal agent is supported beyond that qualifier.
Status epilepticus involves sustained or recurrent seizure activity without return to baseline between episodes. The grounding specifically links the generalized tonic-clonic form with neuronal injury and respiratory and metabolic dysfunction. The literature also covers pathology, metabolism, and genetics, but no more specific mechanism is provided here.
The supplied grounding does not support specific risk factors for status epilepticus. It does indicate that the condition is studied in relation to chemically induced cases, but no generalizable risk factors are stated.
The grounding supports drug therapy as a major literature focus, but it does not provide a full treatment algorithm. Midazolam is the only co-studied drug named, indicating benzodiazepine-based acute treatment is within the literature scope. No other treatment classes or management details are supported by the supplied material.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.